NMR Experiment |
---|
Experiment | Type | Sample Contents | Solvent | Ionic Strength | pH | Pressure | Temperature (K) | Spectrometer |
---|
1 | 2D 1H-15N HSQC | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
2 | 2D 1H-13C HSQC | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
4 | 3D HNCO | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
11 | 3D HCACO | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
10 | 3D HNCACB | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
9 | 3D CBCA(CO)NH | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
8 | 3D C(CO)NH | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
7 | 3D H(CCO)NH | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
6 | 3D HCCH-COSY | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
5 | 3D HCCH-TOCSY | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
3 | 3D HBHA(CO)NH | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
16 | 3D 1H-13C NOESY aliphatic | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
15 | 3D 1H-15N NOESY | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 uM Zinc chloride, 1 mM [U-13C; U-15N] Microphthalmia-associated transcription factor, 1.2 mM TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
14 | 2D 1H-13C HSQC | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
13 | 2D 1H-15N HSQC | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
12 | 3D HNCO | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
26 | 3D HCACO | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
25 | 3D HNCACB | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
24 | 3D CBCA(CO)NH | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
23 | 3D C(CO)NH | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
22 | 3D H(CCO)NH | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
21 | 3D HCCH-COSY | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
20 | 3D HCCH-TOCSY | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
19 | 3D HBHA(CO)NH | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
18 | 3D 1H-13C NOESY aliphatic | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
17 | 3D 1H-13C NOESY aromatic | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |
29 | 3D 1H-15N NOESY | 20 mM 2-(N-morpholino)ethanesulfonic acid (MES), 5 mM beta mercaptoethanol, 10 mM Zinc chloride, 1.15 mM Microphthalmia-associated transcription factor, 0.95 mM [U-13C; U-15N] TAZ2 domain of p300 | 95% H2O/5% D2O | 20 mM | 6.0 | 1 atm | 308 | Varian INOVA 600 |